Vanguard Group Inc Cns Pharmaceuticals, Inc. Transaction History

Vanguard Group Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.19 - $292.65 $4,923 - $7.58 Million	25,912 Added 6.06%	453,615 $81,000
Q1 2022 May 13, 2022	SELL	$0.26 - $1.05 $47,243 - $190,791	-181,706 Reduced 29.82%	427,703 $146,000
Q3 2021 Nov 12, 2021	BUY	$1.4 - $1.98 $14,140 - $19,998	10,100 Added 1.69%	609,409 $908,000
Q2 2021 Aug 13, 2021	BUY	$1.71 - $2.42 $1.02 Million - $1.45 Million	599,309 New	599,309 $1.18 Million

100

Ticker CNSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,032,500
Market Cap $4.4M
Description
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme....

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.